2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: A new class of selective orexin 2 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6405-6407

  Micheli, Fabrizio ^a   Antolini, Marinella ^a   Di Fabio, Romano ^a   Pellacani, Annalisa ^a   Pozzan, Alfonso ^a  

^a GSK   (Italy)

Author keywords

Commercial products; Orexin; Orexin 2 antagonist; Selective

Indexed keywords

2 METHYL 3 FURANYL 4H 1,2,4 TRIAZOL 3 YLTHIOAMIDE; DOPAMINE RECEPTOR; OREXIN 2 RECEPTOR; POTASSIUM CHANNEL HERG; RECEPTOR BLOCKING AGENT; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; NONHUMAN;

ANIMALS; HUMANS; MODELS, MOLECULAR; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 77958044157     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.090     Document Type: Article

References (14)

1. L. De Lecea, T.S. Kilduff, and C. Peyron Proc. Natl. Acad. Sci. U.S.A. 95 1998 322
2. T. Sakurai, A. Amemiya, and M. Ishii Cell 92 1998 573
3. C. Brisbare-Roch, J. Dingemanse, and R. Koberstein Nat. Med. 13 2007 150
4. P.J. Coleman, and J.J. Renger Expert Opin. Ther. Pat. 20 2010 307
5. A.J. Roecker, and P.J. Coleman Curr. Top. Med. Chem. 8 2008 977
6. Gatfield, J.; Brisbare-Roch, C.; Jenck, F.; Boss, C. ChemMedChem Early View, doi: 10.1002/cmdc.201000132.
7. Di Fabio, R.; Gerrard, P.; Porter, R.; Stemp, G.; Nash, D.; Branch, C.; Massagrande, M.; Poffe, A.; Piccoli, L.; Braggio, S.; Ratti, E. Abstracts of Papers, 238th ACS National Meeting, Aug 16-20, 2009; Washington, DC, United States, 2009.
8. i by the modified Cheng-Prusoff equation.
9. Initial global minimum-energy structures for molecule 5 were generated using Spartan '02 (from Wavefunction Inc.) using the conformer distribution module and the merck force field (MMFF). The global minimum structures was then fully optimized at the SCF level with the 6-31G basis set. Successively density and electrostatic potential were calculated for the global minimum.
10. i.
11. P.E. Brandish, L.A. Hill, W. Zheng, and E.M. Scolnick Anal. Biochem. 313 2003 311
12. J.H. Gaddum Pharmacol. Rev. 9 1957 211
13. O. Arunlakshana, and H.O. Schild Br. J. Pharmacol. 14 1959 48
14. All the compounds reported (5-37) are commercially available by different vendors including Asinex (www.asinex.com ).